NCT03262740View on ClinicalTrials.gov

The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients

PHASE1CompletedINTERVENTIONAL
Enrollment

58

Participants

Timeline

Start Date

September 11, 2017

Primary Completion Date

December 19, 2017

Study Completion Date

January 30, 2018

Conditions
Rheumatoid Arthritis
Interventions
DRUG

BMS-986195

Oral administration of specified dose on specified days

DRUG

Loestrin 1.5/30 (1.5 mg norethindrone acetate/30 μg ethinyl estradiol)

Oral Contraceptive

Trial Locations (2)

33143

Miami Research Associates, South Miami

84124

PRA Health Sciences, Salt Lake City

Sponsors
All Listed Sponsors
lead

Bristol-Myers Squibb

INDUSTRY

NCT03262740 - The Effect of BMS-986195 Combined With an Oral Contraceptive (Ethinyl Estradiol/Norethindrone) in Healthy Female Patients | Biotech Hunter | Biotech Hunter